| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2022-03-07 02:49:08 UTC |
|---|
| HMDB ID | HMDB0001139 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Prostaglandin F2a |
|---|
| Description | Prostaglandin F2a (PGF2) is one of the earliest discovered and most common prostaglandins. It is actively biosynthesized in various organs of mammals and exhibits a variety of biological activities, including contraction of pulmonary arteries. It is used in medicine to induce labor and as an abortifacient. PGF2a binds to the Prostaglandin F2 receptor (PTGFR) which is a member of the G-protein coupled receptor family. PGF2-alpha mediates luteolysis. Luteolysis is the structural and functional degradation of the corpus luteum (CL) that occurs at the end of the luteal phase of both the estrous and menstrual cycles in the absence of pregnancy. PGF2 may also be involved in modulating intraocular pressure and smooth muscle contraction in the uterus and gastrointestinal tract sphincters. PGF2 is mainly synthesized directly from PGH2 by PGH2 9,11-endoperoxide reductase. A small amount of PGF2 is also produced from PGE2 by PGE2 9-ketoreductase. A PGF2 epimer has been reported to exhibit various biological activities, and its levels are increased in bronchoalveolar lavage fluid, plasma, and urine in patients with mastocytosis and bronchial asthma. PGF2 is synthesized from PGD2 by PGD2 11-ketoreductase. (PMID: 16475787 ). Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
|---|
| Structure | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4+,13-12+/t15-,16+,17+,18-,19+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (+)-Prostaglandin F2a | HMDB | | (5Z,13E)-(15S)-9-alpha,11-alpha,15-Trihydroxyprosta-5,13-dienoate | HMDB | | (5Z,13E)-(15S)-9-alpha,11-alpha,15-Trihydroxyprosta-5,13-dienoic acid | HMDB | | (5Z,13E,15S)-9a,11a,15-Trihydroxyprosta-5,13-dien-1-Oate | HMDB | | (5Z,13E,15S)-9a,11a,15-Trihydroxyprosta-5,13-dien-1-Oic acid | HMDB | | (5Z,9a,11a,13E,15S)-9,11,15-Trihydroxy-prosta-5,13-dien-1-Oate | HMDB | | (5Z,9a,11a,13E,15S)-9,11,15-Trihydroxy-prosta-5,13-dien-1-Oic acid | HMDB | | (9alpha,11alpha,15)-Trihydroxyprosta-(5Z,13E)-dien-1-Oate | HMDB | | (9alpha,11alpha,15)-Trihydroxyprosta-(5Z,13E)-dien-1-Oic acid | HMDB | | 7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoate | HMDB | | 7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid | HMDB | | 9,11,15-Trihydroxy-(5Z,9a,11a,13E,15S)-prosta-5,13-dien-1-Oate | HMDB | | 9,11,15-Trihydroxy-(5Z,9a,11a,13E,15S)-prosta-5,13-dien-1-Oic acid | HMDB | | 9,11,15-Trihydroxyprosta-5Z,13E-dien-1-Oate | HMDB | | 9,11,15-Trihydroxyprosta-5Z,13E-dien-1-Oic acid | HMDB | | 9a,11a,15(S)-Trihydroxy-5-cis-13-trans-prostadienoate | HMDB | | 9a,11a,15(S)-Trihydroxy-5-cis-13-trans-prostadienoic acid | HMDB | | 9a,11a-PGF2 | HMDB | | 9a,11a-PGF2a | HMDB | | Amoglandin | HMDB | | Cyclosin | HMDB | | Dinifertin | HMDB | | Dinoprost | HMDB | | Enzaprost | HMDB | | Enzaprost F | HMDB | | F2a Isoprostane | HMDB | | Glandin N | HMDB | | L-PGF2-alpha | HMDB | | L-Prostaglandin F2-alpha | HMDB | | Panacelan | HMDB | | PGF2a | HMDB | | Prostaglandin F2 | HMDB | | Prostamate | HMDB | | Prostarmon F | HMDB | | Prostin F 2 alpha | HMDB | | Protamodin | HMDB | | 9alpha,11beta PGF2 | HMDB | | 9alpha,11beta-PGF2 | HMDB | | Estrofan | HMDB | | F2 alpha, Prostaglandin | HMDB | | F2alpha, Prostaglandin | HMDB | | PGF2 | HMDB | | PGF2 alpha | HMDB | | PGF2alpha | HMDB | | Prostaglandin F2 alpha | HMDB | | Prostaglandin F2alpha | HMDB | | alpha, PGF2 | HMDB |
|
|---|
| Chemical Formula | C20H34O5 |
|---|
| Average Molecular Weight | 354.481 |
|---|
| Monoisotopic Molecular Weight | 354.240624198 |
|---|
| IUPAC Name | (5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoic acid |
|---|
| Traditional Name | 5-trans-PGF2α |
|---|
| CAS Registry Number | 551-11-1 |
|---|
| SMILES | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O |
|---|
| InChI Identifier | InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4+,13-12+/t15-,16+,17+,18-,19+/m0/s1 |
|---|
| InChI Key | PXGPLTODNUVGFL-UAAPODJFSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Fatty Acyls |
|---|
| Sub Class | Eicosanoids |
|---|
| Direct Parent | Prostaglandins and related compounds |
|---|
| Alternative Parents | |
|---|
| Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Hydroxy fatty acid
- Cyclopentanol
- Fatty acid
- Unsaturated fatty acid
- Cyclic alcohol
- Secondary alcohol
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxide
- Organic oxygen compound
- Alcohol
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 30 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | 4.39 | BODOR,H & HUANG,M (1992) |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.99 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.6993 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.76 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 65.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2585.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 196.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 169.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 178.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 206.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 552.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 452.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 161.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1144.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 494.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1368.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 335.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 372.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 368.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 167.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 11.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Prostaglandin F2a,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C | 2883.7 | Semi standard non polar | 33892256 | | Prostaglandin F2a,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O | 2784.6 | Semi standard non polar | 33892256 | | Prostaglandin F2a,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O | 2765.8 | Semi standard non polar | 33892256 | | Prostaglandin F2a,1TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C | 2816.1 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C | 2755.7 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C | 2746.0 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2827.9 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O | 2750.7 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C | 2762.8 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C | 2742.2 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C | 2718.1 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2744.9 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2730.6 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C | 2713.7 | Semi standard non polar | 33892256 | | Prostaglandin F2a,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2746.0 | Semi standard non polar | 33892256 | | Prostaglandin F2a,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3139.4 | Semi standard non polar | 33892256 | | Prostaglandin F2a,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O | 2997.0 | Semi standard non polar | 33892256 | | Prostaglandin F2a,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O | 2980.6 | Semi standard non polar | 33892256 | | Prostaglandin F2a,1TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C | 3080.5 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3245.1 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3232.7 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3363.9 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O | 3197.2 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TBDMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C | 3243.4 | Semi standard non polar | 33892256 | | Prostaglandin F2a,2TBDMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C | 3227.3 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3429.7 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3490.6 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3479.2 | Semi standard non polar | 33892256 | | Prostaglandin F2a,3TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C | 3432.6 | Semi standard non polar | 33892256 | | Prostaglandin F2a,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3625.0 | Semi standard non polar | 33892256 |
|
|---|
| General References | - Grinsted J, Byskov AG: Meiosis-inducing and meiosis-preventing substances in human male reproductive organs. Fertil Steril. 1981 Feb;35(2):199-204. [PubMed:7202743 ]
- Catanzarite VA: Prophylactic intramyometrial carboprost tromethamine does not substantially reduce blood loss relative to intramyometrial oxytocin at routine cesarean section. Am J Perinatol. 1990 Jan;7(1):39-42. [PubMed:2403792 ]
- Carr BR, Milburn J Jr, Wright EE, Simpson ER: Adenylate cyclase activity in neocortex and fetal zone membrane fractions of the human fetal adrenal gland. J Clin Endocrinol Metab. 1985 Apr;60(4):718-22. [PubMed:2982905 ]
- Negrel R, Gaillard D, Ailhaud G: Prostacyclin as a potent effector of adipose-cell differentiation. Biochem J. 1989 Jan 15;257(2):399-405. [PubMed:2539085 ]
- Hammarstrom S, Hamberg M, Samuelsson B, Duell EA, Stawiski M, Voorhees JJ: Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc Natl Acad Sci U S A. 1975 Dec;72(12):5130-4. [PubMed:1061097 ]
- Steele GL, Leung PC: Intragonadal signalling mechanisms in the control of steroid hormone production. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):515-22. [PubMed:1562522 ]
- Ciabattoni G, Pugliese F, Spaldi M, Cinotti GA, Patrono C: Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine. J Endocrinol Invest. 1979 Apr-Jun;2(2):173-82. [PubMed:489926 ]
- Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C: Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003 Jul 1;107(25):3199-203. Epub 2003 Jun 16. [PubMed:12810609 ]
- Komoto J, Yamada T, Watanabe K, Woodward DF, Takusagawa F: Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost. Biochemistry. 2006 Feb 21;45(7):1987-96. [PubMed:16475787 ]
|
|---|